Advances in the Development of Hydrophilic Matrix Tablets for Oral Extended Drug Delivery
Posted on December 17, 2013
By: Peter Timmins, Executive Director; Jonathan Brown, Principal Scientist; Sarah Hanley, Research Scientist
Bristol-Myers Squibb
Introduction Oral extended delivery dosage forms offer advantages in the treatment of chronic diseases. The absorption profile that these dosage forms produce can lead, relative to conventional immediate release formulations of a drug, to a lower maximum plasma drug concentration, a delayed time to...
To read the full article and other articles in this issue, please register for a free account or log in.
We will not sell or give your information to a third party. See our Privacy Policy
Related Topics and Keywords
Bristol-Myers Squibb, dissolution, drug diffusion, erosion of the dosage form, formulation, gelling, hydrophilic, Hydrophilic Matrix Tablets, kinetic modelling, magnetic resonance imaging, Oral Extended Drug Delivery, Percolation theory, polymer hydration, polymer swelling
Subscribe to our FREE newsletter and WEBINAR UPDATES
We will not sell or give your information to a third party. See our Privacy Policy
